|
Piperazine Citrate
(pi per' a zeen sit' rate).
Piperazine, 2-hydroxy-1,2,3-propanetricarboxylate (3:2), hydrate. Piperazine citrate (3:2) hydrate Anhydrous 642.66 » Piperazine Citrate contains not less than 98.0 percent and not more than 100.5 percent of (C4H10N2)3· 2C6H8O7, calculated on the anhydrous basis.
Packaging and storage
Preserve in well-closed containers.
Identification
B:
In the test for Chromatographic purity, the principal spot in the chromatogram of Test solution 2, observed after spraying with the ninhydrin solutions, corresponds in RF value, color, and size to that in the chromatogram of Standard solution 1.
C:
It responds to the tests for Citrate
Water, Method I
Chromatographic purity
Solvent
Prepare a mixture of 13.5 N ammonium hydroxide and dehydrated alcohol (3:2).
Standard solution 1
Prepare a solution of USP Piperazine Citrate RS in Solvent containing 10 mg per mL.
Standard solution 2
Prepare a solution of ethylenediamine in Solvent containing 0.25 mg per mL.
Standard solution 3
Prepare a solution of triethylenediamine in Solvent containing 0.25 mg per mL.
Test solution 1
Prepare a solution of Piperazine Citrate in Solvent containing 100 mg per mL.
Test solution 2
Mix 1 mL of Test solution 1 and 9 mL of Solvent.
Resolution solution
Prepare a solution in Solvent containing 0.25 mg of triethylenediamine and 10 mg of Piperazine Citrate per mL.
Procedure
Apply separate 5-µL portions of Standard solution 1, Standard solution 2, Standard solution 3, Resolution solution, Test solution 1, and Test solution 2 to a suitable thin-layer chromatographic plate (see Chromatography
Assay
Dissolve about 200 mg of Piperazine Citrate, accurately weighed, in 100 mL of glacial acetic acid, warming slightly if necessary to effect solution. Add crystal violet TS, and titrate with 0.1 N perchloric acid VS. Perform a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 10.71 mg of (C4H10N2)3·2C6H8O7.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 4338
Pharmacopeial Forum: Volume No. 34(1) Page 106
|